¼¿ï´ëÇб³º´¿ø Á¦2ȸ ´ëÇÑÀ§¾ÏÇÐȸ ´ÙÇÐÁ¦ Áý´ãȸ : 2022-11-17±³À°ÀÏÀÚ : 2022-11-17
±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ¾Ï¿¬±¸¼Ò 2Ãþ ÀÌ°ÇÈñȦ
±³À°ÁÖÁ¦ : (
¿ÀÇÁ¶óÀÎ) Á¦2ȸ ´ëÇÑÀ§¾ÏÇÐȸ ´ÙÇÐÁ¦ Áý´ãȸÁÖÃÖ±â°ü : ´ëÇÑÀ§¾ÏÇÐȸ
´ã´çÀÚ : ±èÁöÇý
¿¬¶ôó : 02-730-3760
À̸ÞÀÏ :
kgca@kgca-i.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í ȸ¿ø(Æò»ýȸ¿ø ¹× ¿¬È¸ºñ ³³ºÎ Á¤È¸¿ø), Àü°øÀÇ, ±ºÀÇ°ü, 65¼¼ ÀÌ»ó, °£È£»ç, Çлý, ±âŸ : ¹«·á / ºñȸ¿ø : 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-17 2Ãþ ÀÌ°ÇÈñȦ 17:30~18:00 µî·Ï .(.)
±âŸ 11-17 2Ãþ ÀÌ°ÇÈñȦ 18:00~18:10 Àλ縻 ±èÇüÈ£(´ëÇÑÀ§¾ÏÇÐȸ ȸÀå)
±³À°½Ã°£ 11-17 2Ãþ ÀÌ°ÇÈñȦ 18:10~19:00 ESD for undifferentiated type EGC ±èÅÂÁØ(»ï¼º¼¿ïº´¿ø)
Åä·Ð 11-17 2Ãþ ÀÌ°ÇÈñȦ 19:00~19:10 Discussion ¾ÈÁö¿µ, ¼Û±ÝÁ¾(»ï¼º¼¿ïº´¿ø, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 11-17 2Ãþ ÀÌ°ÇÈñȦ 19:10~20:00 Recurrent GIST refractory to medical therapy including chemotherapy or targeted agents ¼ÛÁ¤È£(¾ÆÁÖÀÇ´ë)
Åä·Ð 11-17 2Ãþ ÀÌ°ÇÈñȦ 20:00~20:10 Discussion ÀÓ¼®¾Æ, ±èÂù±Ô(¼¿ïÀÇ´ë, ±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 11-17 2Ãþ ÀÌ°ÇÈñȦ 20:10~21:00 Gastric collision tumors, comprising adenocarcinoma and MALT lymphoma: treatment options including chemotherapy, radiation therapy, and surgery ¿À¼ºÀº(»ï¼º¼¿ïº´¿ø)
Åä·Ð 11-17 2Ãþ ÀÌ°ÇÈñȦ 21:00~21:10 Discussion À̼ºÇÐ, ÀÌÁ¾¼®(¼¿ï¼º¸ðº´¿ø, ¼¿ï¾Æ»êº´¿ø)
±âŸ 11-17 2Ãþ ÀÌ°ÇÈñȦ 21:10~21:20 ¸ÎÀ½¸» ÇÑ»ó¿í(´ëÇÑÀ§¾ÏÇÐȸ ÀÌ»çÀå)